Predicting neoadjuvant chemotherapy response of muscle-invasive bladder cancer using patient-derived zebrafish xenograft model: multi-institutional prospective study

Predicting neoadjuvant chemotherapy response of muscle-invasive bladder cancer using patient-derived zebrafish xenograft model: multi-institutional prospective study - Bladder cancer patient-derived zebrafish xenograft model

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054119

Enrollment

100

Registered

2024-05-01

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-invasive bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. New case of muscle-invasive bladder cancer 2. Tumors of sufficient amount of transurethral resection 3. Patients who receive neoadjuvant platinum-based chemotherapy 4. Patients who receive radical cystectomy 5. Patients with available clinical and pathological information 6. Patients who consented.

Exclusion criteria

Exclusion criteria: Patients who are not appropriate to enter the clinical study.

Design outcomes

Primary

Measure	Time frame
Bladder cancer tissue collected transurethrally before NAC from a patient scheduled to undergo radical cystectomy after neoadjuvant chemotherapy (NAC) with a platinum-based anticancer drug for muscle-invasive bladder cancer. Transplant into zebrafish and evaluate the effectiveness of platinum-based anticancer drugs. The results will be compared with the pathological evaluation of the total cystectomy specimen after NAC, and the concordance rate will be the primary endpoint.	—

Measure

Time frame

Bladder cancer tissue collected transurethrally before NAC from a patient scheduled to undergo radical cystectomy after neoadjuvant chemotherapy (NAC) with a platinum-based anticancer drug for muscle-invasive bladder cancer. Transplant into zebrafish and evaluate the effectiveness of platinum-based anticancer drugs. The results will be compared with the pathological evaluation of the total cystectomy specimen after NAC, and the concordance rate will be the primary endpoint.

—

Countries

Japan

Contacts

Public ContactYusuke Sugino

Mie University Graduate School of Medicine Nephro-Urologic Surgery and Andrology

tinoue28@med.mie-u.ac.jp0592315026

Outcome results